



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Febuxostat (Standard)

Cat. No.:	HY-14268R
CAS No.:	144060-53-7
Molecular Formula:	C ₁₆ H ₁₆ N ₂ O ₃ S
Molecular Weight:	316.37
Target:	Xanthine Oxidase
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Febuxostat (Standard) is the analytical standard of Febuxostat. This product is intended for research and analytical applications. Febuxostat (TEI 6720) is a potent, selective and non-purine xanthine oxidase (XO) inhibitor with a K _i value of 0.6 nM. Febuxostat has the potential for the research of hyperuricemia and gout ^{[1][2][3]} .
IC ₅₀ & Target	Ki: 0.6 nM (Xanthine oxidase) ^[1]

REFERENCES

- [1]. Takano Y, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. *Life Sci*, 2005, 76(16), 1835-1847.
- [2]. Sanchez-Lozada LG, et al. Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. *Am J Physiol Renal Physiol*, 2008, 294(4), F710-F718.
- [3]. Sanchez-Lozada LG, et al. Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. *Nephron Physiol*, 2008, 108(4), p69-p78.
- [4]. Nomura J, et al. Xanthine oxidase inhibition by febuxostat attenuates experimental atherosclerosis in mice. *Sci Rep*. 2014 Apr 1;4:4554.
- [5]. Karve AV, et al. Evaluation of effect of allopurinol and febuxostat in behavioral model of depression in mice. *Indian J Pharmacol*. 2013 May-Jun;45(3):244-7.
- [6]. Khames A, et al. Ameliorative effects of sildenafil and/or febuxostat on doxorubicin-induced nephrotoxicity in rats. *Eur J Pharmacol*. 2017 Jun 15;805:118-124.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA